GlassScriptPhysician profile
Francis E Salazar
NPI 1093923849
$28,817.15
in general payments reported to CMS, 2019-2025
52 companies · $2,758 in 2025
The $2,758 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,050 · 2020: $3,646 · 2021: $4,212 · 2022: $3,461 · 2023: $5,182 · 2024: $3,509 · 2025: $2,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,448.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,857.84 | 2019-2025 | Andexxa, Airsupra, Breztri |
| Abbvie INC. | $3,667.48 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $2,836.06 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $2,170.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $1,375.58 | 2019-2023 | |
| Novo Nordisk INC | $1,320.97 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $1,155.46 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $952.49 | 2019-2025 | Descovy, Epclusa, Veklury |
| Bayer Healthcare Pharmaceuticals INC. | $922.30 | 2021-2025 | |
| Horizon Therapeutics Plc | $824.93 | 2019-2022 | |
| Pfizer INC. | $819.53 | 2019-2025 | |
| Lilly USA, LLC | $670.34 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $643.89 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.12 | 2020-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $573.53 | 2022-2025 | Caplyta |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $568.83 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $491.06 | 2022-2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $378.31 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $374.99 | 2021-2023 | Camzyos |
| Melinta Therapeutics, LLC | $374.97 | 2023-2025 | Rezzayo |
| Nestle Healthcare Nutrition INC. | $294.57 | 2020-2022 | |
| Amgen INC. | $280.69 | 2019-2024 | Repatha, Otezla |
| Collegium Pharmaceutical, INC. | $264.39 | 2019-2021 | |
| Shionogi INC | $249.98 | 2023-2024 | Fetroja |
| Janssen Biotech, INC. | $247.21 | 2021-2023 | Imbruvica |
| Nevro Corp. | $245.31 | 2022-2023 | Senza |
| Merck Sharp & Dohme LLC | $229.00 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $222.13 | 2019 | |
| Alkermes, INC. | $220.89 | 2022-2024 | Aristada, Lybalvi |
| Exact Sciences Corporation | $170.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $167.21 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $163.76 | 2023-2024 | Freestyle Libre 3, Freestyle Libre |
| Aimmune Therapeutics, INC. | $147.46 | 2024-2025 | Zenpep |
| Genzyme Corporation | $126.42 | 2023 | |
| Shire North American Group INC | $125.66 | 2019 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2023 | Rexulti |
| Octapharma USA, INC. | $122.41 | 2023 | Octagam Immune Globulin (Human) |
| Ipsen Biopharmaceuticals, INC | $122.38 | 2019 | |
| Csl Behring | $95.76 | 2023 | Hemgenix |
| Intuity Medical INC | $75.00 | 2022 | |
| Boston Scientific Corporation | $65.17 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $49.51 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $22.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.58 | 2021 | |
| Pacira Therapeutics, INC. | $20.19 | 2020 | |
| Linus Health, INC. | $19.40 | 2022 | |
| Incyte Corporation | $17.26 | 2025 | Niktimvo |
| Lucid Diagnostics INC. | $16.41 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.84 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Salazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.